相关实验视频

Updated: Jan 11, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

开发一种基因编码和强大的PDE6D抑制剂

Atanasio Gómez-Mulas¹, Elisabeth Schaffner-Reckinger¹, Hanne Peeters²

¹Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 2 place de l'Université, 4365, Esch-sur-Alzette, Luxembourg.

Chembiochem : a European journal of chemical biology

|November 18, 2025

概括

研究人员开发了基因编码的PDE6D抑制剂,如SNAP-STI,灵感来自自然货物. 这些新型抑制剂显示出比小分子更高的功效,但不能有效地阻止K-Ras信号传递,这表明PDE6D不是理想的癌症标.

科学领域:

生物化学生物化学
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

基化酶6D (PDE6D) 是前化蛋白的伴侣,包括致癌性K-Ras.
小分子抑制剂的PDE6D面临的挑战是水溶性差.
开发有效的抑制剂对于理解PDE6D在癌症等疾病中的作用至关重要.

研究的目的:

开发基因编码的PDE6D抑制剂,以自然高亲和力货物为灵感.
为了比较这些新型抑制剂与现有的小分子抑制剂的功效.
评估PDE6D抑制对K-Ras膜定和下游信号的有效性.

主要方法:

基于PDE6D自然载荷的基因编码抑制剂的设计和合成.
在体外测试以评估PDE6D结合抑制.
基于细胞的测试来测量K-Ras膜定和MAPK信号传递.
新型抑制剂与已确定的小分子抑制剂的比较.

主要成果:

基因编码的抑制剂SNAP-STI,一种法尼西化四,对PDE6D有很高的亲和力.
与小分子抑制剂相比,SNAP-STI在阻断法尼西拉载荷结合方面表现出更大的功效.
通过SNAP-STI抑制K-Ras膜定和MAPK信号传递是最小的,与PDE6D敲击效应保持一致.

结论:

基因编码的抑制剂为向PDE6D提供了有效的策略.
对于有效的K-Ras膜定和MAPK抑制,PDE6D不是一个合适的替代标.
这项研究为设计用于生物研究和目标验证的高亲和度PDE6D抑制剂建立了可通用的方法.

关键词:

在PDE6D中,它是PDE6D.拉斯拉斯拉斯拉斯拉斯拉斯拉斯拉斯拉斯拉索病症是一种RAS病症.癌症癌症癌症癌症癌症抑制剂抑制剂抑制剂

更多相关视频

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...